Intense 68Ga-OncoFAP Uptake as a New Promising Diagnostic Biomarker in Cardiac Sarcoidosis

David Ventura,Michael Schäfers,Ali Yilmaz,Lars Eckardt,Dennis Korthals
DOI: https://doi.org/10.1097/rlu.0000000000005214
IF: 10.6
2024-05-05
Clinical Nuclear Medicine
Abstract:A 72-year-old man revealed typical findings of cardiac sarcoidosis on cardiovascular MRI. However, 18F-FDG PET showed no hypermetabolism. Therefore, immunosuppression was not initiated. After 2 years, ventricular arrhythmias and heart failure worsened. 68Ga–fibroblast activation protein inhibitor PET was initiated to evaluate potential adverse remodeling due to progressive myocardial fibrosis. A second 18F-FDG PET still revealed no hypermetabolism, and the patient received an implanted cardioverter defibrillator after electrophysiological risk stratification. We present a case of intense fibroblast activation despite a missing 18F-FDG uptake (mismatch).
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?